Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2025-12-25 @ 11:18 PM
Study NCT ID:
NCT07170293
Status:
RECRUITING
Last Update Posted:
2025-09-12
First Post:
2025-09-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Sponsor:
Tianjin Medical University Second Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2027-08-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-06
First Submit QC Date:
None
Study First Post Date:
2025-09-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-11
Last Update Post Date:
2025-09-12
Last Update Post Date Type:
ESTIMATED